Goran Radegran
Overview
Explore the profile of Goran Radegran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
2452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jumatate R, Werther-Evaldsson A, Ingvarsson A, Radegran G, Meurling C, Ostenfeld E
Eur Heart J Imaging Methods Pract
. 2024 Dec;
2(3):qyae128.
PMID: 39737112
Aims: Right ventricular (RV) failure causes high mortality in patients with pulmonary arterial hypertension (PAH). RV stroke work index (RVSWi) poses as a potential predictor of outcome. We evaluated how...
2.
Grov I, Authen A, Arora S, Bergh N, Rolid K, Gustafsson F, et al.
Clin Transplant
. 2024 Nov;
38(11):e70028.
PMID: 39575520
Background: Calcineurin inhibitors (CNIs) are associated with long-term complications after heart transplantation (HTx). Everolimus (EVR)-based immunosuppression allows for CNI withdrawal. We used data from The Scandinavian heart transplant everolimus de...
3.
Hjalmarsson C, Thakur T, Weiss T, Bjorklund E, Papageorgiou J, Radegran G, et al.
J Heart Lung Transplant
. 2024 Nov;
PMID: 39536922
Background: Multicomponent improvement (MCI) is a novel endpoint for predicting survival in patients with pulmonary arterial hypertension (PAH), included in the sotatercept clinical program. For the first time, we investigated...
4.
Lindholm A, Kjellstrom B, Radegran G, Arheden H, Ostenfeld E
J Cardiovasc Magn Reson
. 2024 Sep;
26(2):101103.
PMID: 39326558
Background: Right ventricular (RV) dyssynchrony or post systolic contraction (PSC) causes inefficient pumping and has not been investigated as a prognostic marker in pulmonary arterial hypertension (PAH). The objective was...
5.
Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209472
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters...
6.
Venkateshvaran A, Bohlin J, Kjellstrom B, Bergstrom E, Nelsson A, Evaldsson A, et al.
Sci Rep
. 2024 Jul;
14(1):17280.
PMID: 39068288
The pathophysiology underlying impaired LV function in PAH remains unclear, with some studies implicating intrinsic myocardial dysfunction and others pointing to LV underfilling. Evaluation of pulmonary vein area (PVA) and...
7.
Bollano E, Andreassen A, Eiskjaer H, Gustafsson F, Radegran G, Gude E, et al.
J Heart Lung Transplant
. 2024 Jul;
43(12):1948-1959.
PMID: 39038562
Background: Early substitution of calcineurin inhibitor (CNI) with mammalian target of rapamycin inhibitors has been shown to improve kidney function and reduce intimal hyperplasia in heart transplant (HTx) recipients but...
8.
Gialamas I, Arvanitaki A, Rosenkranz S, Wort S, Radegran G, Badagliacca R, et al.
J Heart Lung Transplant
. 2024 May;
43(9):1383-1394.
PMID: 38744353
Background: Contemporary patients with pulmonary arterial hypertension (PAH) are older and exhibit cardiovascular or/and lung comorbidities. Such patients have typically been excluded from major PAH drug trials. This systematic review...
9.
Helleberg S, Engel A, Ahmed S, Ahmed A, Radegran G
Am Heart J Plus
. 2024 Apr;
20:100190.
PMID: 38560419
Introduction: Left heart failure (LHF) is commonly complicated by pulmonary hypertension (PH), increasing morbidity and mortality. The present study aimed to evaluate the prognostic value of inflammatory proteins in LHF...
10.
Ahmed S, Ahmed A, Radegran G
Pulm Circ
. 2024 Feb;
14(1):e12340.
PMID: 38317859
No abstract available.